



an Open Access Journal by MDPI

Unraveling the Epigenetic Blueprint: Exploring DNA Methylation and Its Integration with Omics in Health and Disease

Guest Editors:

Dr. Priyadarshini Kachroo

Department of Biomedical and Health Informatics, Rutgers School of Health Professions, Rutgers, The State University of New Jersey, Newark, NJ, USA

Dr. Rinku Sharma

Channing Division of Network Medicine (CDNM), Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions:

closed (31 May 2026)

Message from the Guest Editors

Epigenetic mechanisms are involved in development, inheritance, and disease. Over the last decade, the field of epigenetics research has grown tremendously, accelerating our understanding of human biology and its interaction with the environment. Several groundbreaking discoveries are continuing to grow in number and scope due to their appealing potential in gene regulation, editing, aging, and preventative interventions for complex diseases.

This Special Issue welcomes original research and methodical or review articles and aims to provide an opportunity to highlight studies involving and integrating epigenetics research, including, but not limited to, data generated through techniques such as ChIP-seq, ATAC-seq, whole-genome DNA methylation such as WGBS or RRBS, EPIC arrays, RNA sequencing, single-cell RNA-seq (scRNA-seq), single-cell epigenetics/epigenomics, metabolomics, proteomics, exposomics, therapeutics, aging, growth and developmental trajectories, multiomics, spatial transcriptomics/epigenomics, and techniques elucidating the role of micro-RNAs and non-coding RNAs in epigenetic modulation.



mdpi.com/si/211946

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)